Kevin Murphy, Fund Manager Schroders, explains his value investing strategy. On average his fund had a yearly 4% outperformance. The fund also invests in smaller companies and has a flexible number of holdings. Murphy's strategy is not like Warren...

Dimitri F. Dimitriou, MSC, Chief Executive Officer of ImmuPharma is talking about the recently closed deal between ImmuPharma and Avion Pharmaceuticals. ImmuPharma announced a deal with Avion Pharmaceuticals about a month ago to have the exclusiv...

We speak with Chris Elliott and Ben Peters from the Evenlode Global Income Fund. This must mostly focusses on the search for companies with stable and growing cash flows preferably combined with dividend payments.

Dimitri F. Dimitriou, MSC, Chief Executive Officer of ImmuPharma is talking about the company, its most successful drugs and new listing on Brussels. ImmuPharma is a drug development company which has been around 20 years now. The company starte...

Sean Markowicz, CFA Strategist Schroders sees a very small group of mega tech companies having a very big influence. This regarding to variables like their stock market returns, revenues and net profits. Passive investors made very huge gains with...

Dominic Nys about investing